FDA Approves Corcept's Lifyorli for Platinum-Resistant Ovarian Cancer

summarizeSummary

Corcept Therapeutics announced FDA approval for Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer, marking a significant positive development and opening a new market.

check_boxKey Events

• FDA Approval Granted

  Lifyorli™ (relacorilant) has received U.S. Food and Drug Administration (FDA) approval in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

• Strong Clinical Efficacy

  The approval is based on positive outcomes from the pivotal ROSELLA trial, which demonstrated a 35% reduction in the risk of death and a 30% reduction in the risk of disease progression for patients treated with Lifyorli plus nab-paclitaxel.

• First-in-Class Drug

  Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA), positioning it as a novel treatment option.

• Significant Market Opportunity

  The treatment targets a substantial patient population, with approximately 20,000 women with platinum-resistant disease in the United States alone who are candidates for new therapy each year.

auto_awesomeAnalysis

This 8-K announces a pivotal FDA approval for Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer. This is a significant positive development, especially given the company's prior setbacks, including a Complete Response Letter for relacorilant in a different indication and a decline in profitability. The approval, based on strong clinical data showing a 35% reduction in death risk and 30% reduction in disease progression, opens a substantial new market opportunity (estimated 20,000 patients annually in the US). As the first FDA-approved selective glucocorticoid receptor antagonist, Lifyorli could become a new standard of care, fundamentally improving Corcept's revenue outlook and investor sentiment.